CL2022001176A1 - Composiciones y métodos para producir una vacuna viral con tamaño de partícula reducida - Google Patents
Composiciones y métodos para producir una vacuna viral con tamaño de partícula reducidaInfo
- Publication number
- CL2022001176A1 CL2022001176A1 CL2022001176A CL2022001176A CL2022001176A1 CL 2022001176 A1 CL2022001176 A1 CL 2022001176A1 CL 2022001176 A CL2022001176 A CL 2022001176A CL 2022001176 A CL2022001176 A CL 2022001176A CL 2022001176 A1 CL2022001176 A1 CL 2022001176A1
- Authority
- CL
- Chile
- Prior art keywords
- methods
- particle size
- compositions
- producing
- viral vaccine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/04—Inactivation or attenuation; Producing viral sub-units
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/04—Inactivation or attenuation; Producing viral sub-units
- C12N7/06—Inactivation or attenuation by chemical treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16151—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16251—Methods of production or purification of viral material
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Se divulgan métodos y una composición que producen una vacuna viral con tamaño de partícula reducida, particularmente para su uso en la producción de vacunas contra el virus de la influenza.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962931909P | 2019-11-07 | 2019-11-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2022001176A1 true CL2022001176A1 (es) | 2023-01-20 |
Family
ID=74104121
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2022001176A CL2022001176A1 (es) | 2019-11-07 | 2022-05-04 | Composiciones y métodos para producir una vacuna viral con tamaño de partícula reducida |
Country Status (11)
Country | Link |
---|---|
US (1) | US20230220356A1 (es) |
EP (1) | EP4054630A2 (es) |
JP (1) | JP2023500873A (es) |
KR (1) | KR20220098370A (es) |
CN (1) | CN114929270A (es) |
AU (1) | AU2020380604A1 (es) |
BR (1) | BR112022008711A2 (es) |
CL (1) | CL2022001176A1 (es) |
IL (1) | IL292699A (es) |
MX (1) | MX2022005513A (es) |
WO (1) | WO2021090067A2 (es) |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1878424A3 (en) | 1999-09-24 | 2008-04-09 | GlaxoSmithKline Biologicals S.A. | Novel vaccine |
GB0024089D0 (en) | 2000-10-02 | 2000-11-15 | Smithkline Beecham Biolog | Novel compounds |
WO2002074336A2 (en) | 2001-02-23 | 2002-09-26 | Glaxosmithkline Biologicals S.A. | Influenza vaccine formulations for intradermal delivery |
US20040096463A1 (en) | 2001-02-23 | 2004-05-20 | Nathalie Garcon | Novel vaccine |
PT2368572T (pt) | 2005-11-04 | 2020-06-16 | Seqirus Uk Ltd | Vacinas com adjuvante dotadas de antigénios não-virião preparados a partir de vírus da gripe cultivado em cultura celular |
NZ587798A (en) * | 2008-03-18 | 2013-06-28 | Novartis Ag | Improvements in the preparation of influenza virus vaccine antigens utilising a phosphate buffer |
WO2011138229A1 (en) | 2010-05-03 | 2011-11-10 | Glaxosmithkline Biologicals S.A. | Novel method |
WO2011138682A2 (en) | 2010-05-06 | 2011-11-10 | Novartis Ag | Organic peroxide compounds for microorganism inactivation |
-
2020
- 2020-11-06 KR KR1020227018894A patent/KR20220098370A/ko unknown
- 2020-11-06 MX MX2022005513A patent/MX2022005513A/es unknown
- 2020-11-06 EP EP20830297.6A patent/EP4054630A2/en active Pending
- 2020-11-06 JP JP2022525700A patent/JP2023500873A/ja active Pending
- 2020-11-06 AU AU2020380604A patent/AU2020380604A1/en active Pending
- 2020-11-06 WO PCT/IB2020/000961 patent/WO2021090067A2/en active Application Filing
- 2020-11-06 BR BR112022008711A patent/BR112022008711A2/pt unknown
- 2020-11-06 US US17/771,625 patent/US20230220356A1/en active Pending
- 2020-11-06 CN CN202080092259.7A patent/CN114929270A/zh active Pending
-
2022
- 2022-05-02 IL IL292699A patent/IL292699A/en unknown
- 2022-05-04 CL CL2022001176A patent/CL2022001176A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
US20230220356A1 (en) | 2023-07-13 |
CN114929270A (zh) | 2022-08-19 |
MX2022005513A (es) | 2022-06-08 |
AU2020380604A1 (en) | 2022-06-09 |
WO2021090067A3 (en) | 2021-06-10 |
WO2021090067A2 (en) | 2021-05-14 |
IL292699A (en) | 2022-07-01 |
EP4054630A2 (en) | 2022-09-14 |
BR112022008711A2 (pt) | 2022-07-19 |
KR20220098370A (ko) | 2022-07-12 |
JP2023500873A (ja) | 2023-01-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022006603A (es) | Vacuna contra el virus de la influenza de amplio espectro. | |
EP4233898A3 (en) | Influenza mrna vaccines | |
WO2017136575A8 (en) | Compositions of influenza hemagglutinin with heterologous epitopes and/or altered maturation cleavage sites | |
UY33297A (es) | Composiciones farmaceuticas que comprenden un polipéptido que comprende al menos un motivo cxxc y antígenos heterólogos y usos de las mismas | |
PH12018000197A1 (en) | Hand, foot, and mouth vaccines and methods of manufacture and use thereof | |
PH12019501569A1 (en) | Universal influenza vaccine compositions | |
MX2017016896A (es) | Vacunas inactivadas contra la influenza canina, metodos para elaborarlas y sus usos. | |
MX2019005102A (es) | Poxvirus quimericos sinteticos. | |
CU20170044A7 (es) | Método mejorado para producir una composición de partículas enterovirales a través de la inactivación del enterovirus y la adsorción en coadyuvantes | |
AR115069A1 (es) | Virus vacuna quimérico sintético | |
MX2018014955A (es) | Vacunas atenuadas vivas del virus de la influenza equina. | |
AU2017241669A1 (en) | Live, attenuated alphavirus constructs and methods and uses thereof | |
EA201890502A1 (ru) | Комбинированная вакцинная композиция для многократного дозирования | |
MX2021003392A (es) | Composiciones de hemaglutinina de influenza con epitopos heterologos y/o sitios de segmentacion de maduracion alterados. | |
CO2020000021A2 (es) | Método para preparar reserva de cepas víricas de trabajo para la influenza, método para preparar la vacuna contra la influenza usando la misma reserva de cepas, y la reserva de cepas víricas preparadas por el mismo método | |
AR104271A1 (es) | Vacuna contra las paperas en base al virus jeryl lynn 2 recombinante | |
EP4008343A3 (en) | Methods and compositions related to increased viral production | |
EP3599247A3 (en) | Recombinant hemagglutinin protein of influenza virus and vaccine containing the same | |
CO6781543A2 (es) | Métodos para producir partículas de virus con glucosilación simplificada de proteínas de superficie | |
CL2022001176A1 (es) | Composiciones y métodos para producir una vacuna viral con tamaño de partícula reducida | |
MX2020004305A (es) | Linea celular eucariota. | |
WO2018175580A3 (en) | Development of an alternative modified live influenza b virus vaccine | |
WO2017011620A3 (en) | Methods and compositions related to increasing the fidelity of influenza a virus for vaccine development | |
MX2020003753A (es) | Composicion nasal de vacuna contra hepatitis b y metodo para producir la misma. | |
MX2023011129A (es) | Mutantes del virus de la influenza b y usos de los mismos. |